Base de datos : MEDLINE
Búsqueda : Metaplasia [Palabras]
Referencias encontradas : 18340 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 1834 va a la página                         

  1 / 18340 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23671731
[Au] Autor:Fajardo CA; Quiroga AJ; Coronado A; Labrador K; Acosta N; Delgado P; Jaramillo C; Bravo MM
[Ad] Dirección:Carlos Alberto Fajardo, Andrés Javier Quiroga, Andrea Coronado, Karen Labrador, María Mercedes Bravo, Cancer and Infectious Agents Research Group, National Cancer Institute, Bogotá 110411, Colombia.
[Ti] Título:CagA EPIYA polymorphisms in Colombian Helicobacter pylori strains and their influence on disease-associated cellular responses.
[So] Fuente:World J Gastrointest Oncol;5(3):50-9, 2013 Mar 15.
[Is] ISSN:1948-5204
[Cp] País de publicación:China
[La] Idioma:eng
[Ab] Resumen:AIM: To investigate the influence of the CagA diversity in Helicobacter pylori (H. pylori) strains from Colombia on the host cell biology. METHODS: Eighty-four H. pylori-cagA positive strains with different Glu-Pro-Ile-Tyr-Ala (EPIYA) motifs patterns, isolated from patients with gastritis (n = 17), atrophic gastritis (n = 17), duodenal ulcer (n = 16), intestinal metaplasia (n = 16) and gastric cancer (n = 18), were included. To determine the integrity of the cag pathogenicity island (cagPAI) we evaluated the presence of cagA, cagT, cagE, and cag10 genes by polymerase chain reaction. AGS gastric epithelial cells were infected with each strain and assayed for translocation and tyrosine phosphorylation of CagA by western blot, secretion of interleukin-8 (IL-8) by enzyme-linked immuno sorbent assay after taking supernatants from cocultures and cell elongation induction. For cell elongation quantification, coculture photographs were taken and the proportion of "hummingbird" cells (> 15 µm) was determined. RESULTS: Overall 72% (60/84) of the strains were found to harbor a functional cagPAI. Levels of phosphorylated CagA were significantly higher for isolates from duodenal ulcer than the ones in strains from gastritis, atrophic gastritis, intestinal metaplasia and gastric cancer (49.1% ± 23.1% vs 21.1% ± 19.5%, P < 0.02; 49.1% ± 23.1% vs 26.2% ± 14.8%, P < 0.045; 49.1% ± 23.1% vs 21.5% ± 19.5%, P < 0.043 and 49.1% ± 23.1% vs 29.5% ± 27.1%, P < 0.047 respectively). We observed variable IL-8 expression levels ranging from 0 to 810 pg/mL and from 8.8 to 1442 pg/mL at 6 h and 30 h post-infection, respectively. cagPAI-defective strains did not induce detectable levels of IL-8 at 6 h post-infection. At 30 h post-infection all strains induced IL-8 expression in AGS cells, although cagPAI-defective strains induced significantly lower levels of IL-8 than strains with a functional cagPAI (57.1 ± 56.6 pg/mL vs 513.6 ± 338.6 pg/mL, P < 0.0001). We did not observe differences in the extent of cell elongation induction between strains with a functional or a defective cagPAI in 6 h cocultures. At 24 h post infection strains with functional cagPAI showed high diversity in the extent of hummingbird phenotype induction ranging from 7% to 34%. cagPAI defective strains induced significantly lower levels of elongation than strains with functional cagPAI with one or more than one EPIYA-C motif (15.1% ± 5.2% vs 18.9% ± 4.7%, P < 0.03; and 15.1% ± 5.2% vs 20.0% ± 5.1%, P < 0.003 respectively). No differences were observed in cellular elongation induction or IL-8 expression among H. pylori strains bearing one and more than one EPIYA-C motifs, neither at 6 h nor at 24 h of coculture. There were no associations between the levels of induction of cell elongation or IL-8 expression and number of EPIYA motifs or pathology. CONCLUSION: The present work describes a lack of association between H. pylori CagA protein EPIYA motifs variations from Colombian isolates and disease-associated cellular responses.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1305
[St] Status:In-Data-Review
[do] DOI:10.4251/wjgo.v5.i3.50


  2 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23290822
[Au] Autor:Russo A; Bronte G; Cabibi D; Bazan V; Cicero G; Bertani A; Rizzo S; Fiorentino E
[Ad] Dirección:Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy. Electronic address: antonio.russo@usa.net.
[Ti] Título:The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg?
[So] Fuente:Crit Rev Oncol Hematol;86(3):278-89, 2013 Jun.
[Is] ISSN:1879-0461
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:Esophageal adenocarcinoma originates from columnar metaplastic epithelium of the distal esophagus. Various steps for this carcinogenetic process are known. Before the onset of high-grade dysplasia and adenocarcinoma, endoscopic surveillance is possible. However, because of the high cost of long-term surveillance, predictive factors for cancer are being evaluated to identify subjects with metaplasia who have a higher risk of developing malignancy. Molecular changes seem suitable for this purpose, but could require a high resource expenditure. While trying to identify the best predictive factors for cancer risk, molecular changes and differences in miRNA expression profile between the various steps leading to cancer could help to clarify Barrett's carcinogenesis. In this attempt to find a molecular explanation for the onset of esophageal adenocarcinoma, it is still difficult to understand whether the molecular changes are causes or effects of the neoplastic phenotypic modifications.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1305
[Sb] Subgrupo de revista:IM
[St] Status:In-Data-Review


  3 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23667752
[Au] Autor:Jo HJ; Lee HS; Kim N; Nam RH; Chang H; Kim MS; Kim SE; Oh JC; Lee DH; Jung HC
[Ad] Dirección:Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
[Ti] Título:Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea.
[So] Fuente:J Neurogastroenterol Motil;19(2):210-8, 2013 Apr.
[Is] ISSN:2093-0879
[Cp] País de publicación:Korea (South)
[La] Idioma:eng
[Ab] Resumen:UNLABELLED: BACKGROUNDAIMS: There has been no report regarding the regression of Barrett's esophagus (BE) by continuous treatment of proton pump inhibitor (PPI). The aim of this study was to determine the regression rate of BE by PPI and predictable markers related to regression. METHODS: Thirty-five patients diagnosed as BE were consecutively enrolled and most of them took continuous PPI. The 25 patients underwent endoscopic surveillance and received biopsy. If the specialized intestinal metaplasia (SIM) was lost at any point of surveillance and did not recur, the case was regarded as the regression group. The proportion of SIM was graded and the mucin phenotype was decided using immunohistochemistry for MUC2, MUC5AC and MUC6. To assess the cell proliferation indexes and the degree of intestinal maturation, immunohistochemistry for Ki67 and CDX2 were performed. RESULTS: The regression of BE occurred in the 11 (44%) patients. The clinical and demographic factors showed no difference between the regression (n = 11) and persistence group (n = 14). The lower grade of SIM (P < 0.001) and gastric predominant mucin phenotype (P = 0.018) were more frequent, and the number of Ki67 positive cell per gland (P = 0.008) and the mean extent of CDX2 (P = 0.022) were lower in the regression group than in the persistence group. CONCLUSIONS: The regression of BE by PPI treatment was frequent in Korea. The immunohistochemical detection of mucin phenotype, grade of SIM, Ki67 and CDX2 expression in Barrett's mucosa could be useful as a predictable marker for regression of SIM in BE.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1305
[Da] Fecha de ingreso para procesamiento:130513
[St] Status:PubMed-not-MEDLINE
[do] DOI:10.5056/jnm.2013.19.2.210


  4 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23552532
[Au] Autor:Haroon S; Faridi N; Lodhi FR; Mujtaba S
[Ad] Dirección:Department of Histopathology, The Aga Khan Hospital, Karachi. saroonakm@yahoo.com
[Ti] Título:Frequency of precancerous lesions in endoscopic gastric biopsies in chronic gastritis.
[So] Fuente:J Coll Physicians Surg Pak;23(4):247-50, 2013 Apr.
[Is] ISSN:1681-7168
[Cp] País de publicación:Pakistan
[La] Idioma:eng
[Ab] Resumen:OBJECTIVE: To determine the frequency of precancerous lesions in endoscopic gastric biopsies of patients with chronic gastritis. STUDY DESIGN: A case series. PLACE AND DURATION OF STUDY: Department of Histopathology, Liaquat National Hospital, Karachi, from July 2008 to January 2009. METHODOLOGY: Over 6 months, 375 endoscopic gastric biopsies of patients with age group of 15-65 years having endoscopic chronic gastritis were included. From final biopsy report, basic information like patient demographics and presence of precancerous lesions i.e. activity (chronic active gastritis), atrophy (atrophic gastritis), intestinal metaplasia and dysplasia were recorded on proforma. Results were described as proportions and frequency. RESULTS: The frequency of precancerous lesions in endoscopic gastric biopsies of patients with chronic gastritis in Karachi was markedly high. Most common lesion was chronic active gastritis as depicted by activity (48.3%); dysplasia (1.3%) was the least common. Proportion of more aggressive precancerous lesions were markedly higher in older age group (> 40 years). CONCLUSION: The precancerous lesions are frequent in endoscopic gastric biopsies of patients with chronic gastritis.
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1304
[Sb] Subgrupo de revista:IM
[St] Status:In-Process
[do] DOI:04.2013/JCPSP.247250


  5 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23378345
[Au] Autor:Nguyen TL; Khurana SS; Bellone CJ; Capoccia BJ; Sagartz JE; Kesman RA; Mills JC; DiPaolo RJ
[Ad] Dirección:Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.
[Ti] Título:Autoimmune gastritis mediated by CD4+ T cells promotes the development of gastric cancer.
[So] Fuente:Cancer Res;73(7):2117-26, 2013 Apr 1.
[Is] ISSN:1538-7445
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:Chronic inflammation is a major risk factor for cancer, including gastric cancers and other gastrointestinal cancers. For example, chronic inflammation caused by autoimmune gastritis (AIG) is associated with an increased risk of gastric polyps, gastric carcinoid tumors, and possibly adenocarcinomas. In this study, we characterized the progression of gastric cancer in a novel mouse model of AIG. In this model, disease was caused by CD4(+) T cells expressing a transgenic T-cell receptor specific for a peptide from the H(+)/K(+) ATPase proton pump, a protein expressed by parietal cells in the stomach. AIG caused epithelial cell aberrations that mimicked most of those seen in progression of human gastric cancers, including chronic gastritis followed by oxyntic atrophy, mucous neck cell hyperplasia, spasmolytic polypeptide-expressing metaplasia, dysplasia, and ultimately gastric intraepithelial neoplasias. Our work provides the first direct evidence that AIG supports the development of gastric neoplasia and provides a useful model to study how inflammation drives gastric cancer.
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1304
[Sb] Subgrupo de revista:IM
[St] Status:In-Process
[do] DOI:10.1158/0008-5472.CAN-12-3957


  6 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23370328
[Au] Autor:Wauters E; Sanchez-Arévalo Lobo VJ; Pinho AV; Mawson A; Herranz D; Wu J; Cowley MJ; Colvin EK; Njicop EN; Sutherland RL; Liu T; Serrano M; Bouwens L; Real FX; Biankin AV; Rooman I
[Ad] Dirección:Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia.
[Ti] Título:Sirtuin-1 regulates acinar-to-ductal metaplasia and supports cancer cell viability in pancreatic cancer.
[So] Fuente:Cancer Res;73(7):2357-67, 2013 Apr 1.
[Is] ISSN:1538-7445
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:The exocrine pancreas can undergo acinar-to-ductal metaplasia (ADM), as in the case of pancreatitis where precursor lesions of pancreatic ductal adenocarcinoma (PDAC) can arise. The NAD(+)-dependent protein deacetylase Sirtuin-1 (Sirt1) has been implicated in carcinogenesis with dual roles depending on its subcellular localization. In this study, we examined the expression and the role of Sirt1 in different stages of pancreatic carcinogenesis, i.e. ADM models and established PDAC. In addition, we analyzed the expression of KIAA1967, a key mediator of Sirt1 function, along with potential Sirt1 downstream targets. Sirt1 was co-expressed with KIAA1967 in the nuclei of normal pancreatic acinar cells. In ADM, Sirt1 underwent a transient nuclear-to-cytoplasmic shuttling. Experiments where during ADM, we enforced repression of Sirt1 shuttling, inhibition of Sirt1 activity or modulation of its expression, all underscore that the temporary decrease of nuclear and increase of cytoplasmic Sirt1 stimulate ADM. Our results further underscore that important transcriptional regulators of acinar differentiation, that is, Pancreatic transcription factor-1a and ß-catenin can be deacetylated by Sirt1. Inhibition of Sirt1 is effective in suppression of ADM and in reducing cell viability in established PDAC tumors. KIAA1967 expression is differentially downregulated in PDAC and impacts on the sensitivity of PDAC cells to the Sirt1/2 inhibitor Tenovin-6. In PDAC, acetylation of ß-catenin is not affected, unlike p53, a well-characterized Sirt1-regulated protein in tumor cells. Our results reveal that Sirt1 is an important regulator and potential therapeutic target in pancreatic carcinogenesis.
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mes de ingreso:1304
[Sb] Subgrupo de revista:IM
[St] Status:In-Process
[do] DOI:10.1158/0008-5472.CAN-12-3359


  7 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:23434259
[Au] Autor:Ruffato A; Mattioli S; Perrone O; Lugaresi M; Di Simone MP; D'Errico A; Malvi D; Aprile MR; Raulli G; Frassineti L
[Ad] Dirección:Division of Thoracic Surgery, Centre for the Study and Therapy of Diseases of the Esophagus, GVM Care and Research, Department of Medical and Surgical Sciences (DIMEC), and Pathology Unit, Felice Addarii Institute, University of Bologna, Italy.
[Ti] Título:Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia.
[So] Fuente:Ann Thorac Surg;95(4):1147-53, 2013 Apr.
[Is] ISSN:1552-6259
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Immunohistochemical profiles of esophageal and cardia adenocarcinoma differ according to the presence or absence of Barrett's epithelium (BIM) and gastric intestinal metaplasia (GIM) in the fundus and antrum. Different lymphatic spreading has been demonstrated in esophageal adenocarcinoma. We investigated the correlation among the presence or absence of intestinal metaplasia in the esophagus and stomach and lymphatic metastases in patients who underwent radical surgery for esophageal and cardia adenocarcinoma. METHODS: The mucosa surrounding the adenocarcinoma and the gastric mucosa were analyzed. The BIM+ patients underwent subtotal esophagectomy and gastric pull up, and the BIM- patients underwent esophagectomy at the azygos vein, total gastrectomy, and esophagojejunostomy. The radical thoracic (station numbers 2, 3, 4R, 7, 8, and 9) and abdominal (station numbers 15 through 20) lymphadenectomy was identical in both procedures except for the greater curvature. RESULTS: One hundred ninety-four consecutive patients were collected in three major groups: BIM+/GIM-, 52 patients (26.8%); BIM-/GIM-, 90 patients (46.4%); BIM-/GIM+, 50 patients (25.8%). Two patients (1%) were BIM+/GIM+. A total of 6,010 lymph nodes were resected: 1,515 were recovered in BIM+, 1,587 in BIM-/GIM+, and 2,908 in BIM-/GIM- patients. The percentage of patients with pN+ stations 8 and 9 was higher in BIM+ (p=0.001), and the percentage of patients with pN+ perigastric stations was higher in BIM- (p=0.001). The BIM-/GIM- patients had a number of abdominal metastatic lymph nodes higher than did the BIM-/GIM+ patients (p=0.0001). CONCLUSIONS: According to the presence or absence of BIM and GIM in the esophagus and cardia, adenocarcinoma correspond to three different patterns of lymphatic metastasization, which may reflect different biologic and carcinogenetic pathways.
[Mh] Términos MeSH primario: Adenocarcinoma/secundario
Esófago de Barrett/etiología
Cardias
Neoplasias Esofágicas/patología
Mucosa Intestinal/patología
Ganglios Linfáticos/patología
Neoplasias Gástricas/patología
[Mh] Términos MeSH secundario: Adenocarcinoma/diagnóstico
Adenocarcinoma/cirugía
Anciano
Anastomosis Quirúrgica
Esófago de Barrett/patología
Endoscopía del Sistema Digestivo
Neoplasias Esofágicas/complicaciones
Neoplasias Esofágicas/cirugía
Esofagectomía
Esófago/cirugía
Femenino
Gastrectomía
Humanos
Yeyuno/cirugía
Metástasis Linfática
Masculino
Metaplasia
Mediana Edad
Tomografia por Emisión de Positrones y Tomografía Computarizada
Pronóstico
Estudios Prospectivos
Neoplasias Gástricas/complicaciones
Neoplasias Gástricas/cirugía
[Pt] Tipo de publicación:COMPARATIVE STUDY; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mes de ingreso:1305
[Sb] Subgrupo de revista:AIM; IM
[Da] Fecha de ingreso para procesamiento:130325
[St] Status:MEDLINE


  8 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:23516872
[Au] Autor:Konorev MR; Matveenko ME; Katina EL
[Ti] Título:[Duodenal polyps: epidemiology, clinical picture, diagnostics].
[So] Fuente:Klin Med (Mosk);90(12):52-5, 2012.
[Is] ISSN:0023-2149
[Cp] País de publicación:Russia (Federation)
[La] Idioma:rus
[Ab] Resumen:This cross-sectional comparative study included 120 patients (68 men and 52 women, mean age 58.3 +/- 14.5 yr) with duodenal polyps (DP) diagnosed by fibroesophagogastroduodenoscopy. Morphological study was conducted in 118 patients. Gastric metaplasia (GM) areas in polyp mucosa (PM) were identified by alcian blue/PAS reaction at pH 1.0 and 2.5. A total of 82859 patients were examined. Endoscopy revealed DP in 0.15% of them. The pH value below 6.5 was documented in duodenal bulb polyps in 85% of the patients having them and in 20% of those with polyps of other localization. Biliary pathology was documented in 80% of the patient with DP in major duodenal papilla and in 2.0% of those with DP of different localization. 66.7% of the patients did not complain of pain in the upper part of the gastrointestinal tract. Erosion of polyp mucosa occurred in 21.2% of the patients (92% of erosions in duodenal bulbs and 56.5% in hyperplastic DP with GM areas). H. pylori was identified in GM areas of bulb DP in 30.4% of the patients. Endoscopic study of 120 patients revealed the following localization of DP: bulbs - 83.4%, postbulbar region - 8.3%, major duodenal papilla - 8.3%. The following morphological types of DP (n = 118) were identified: hyperplastic DP - 49.2%, epithelial tumours - 16.1%, non-epithelial tumours - 1.7%, inflamed mucosal areas - 33.0%.
[Mh] Términos MeSH primario: Duodeno/patología
Pólipos Intestinales/diagnóstico
Pólipos Intestinales/epidemiología
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Anciano de 80 o más Años
Estudios Transversales
Diagnóstico Diferencial
Endoscopía Gastrointestinal
Femenino
Humanos
Hiperplasia/patología
Incidencia
Mucosa Intestinal/patología
Masculino
Mediana Edad
República de Belarús/epidemiología
Estudios Retrospectivos
Adulto Joven
[Pt] Tipo de publicación:COMPARATIVE STUDY; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mes de ingreso:1305
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:130322
[St] Status:MEDLINE


  9 / 18340 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
[PMID]:23488270
[Au] Autor:Vasilevskii DI; Silant'ev DS; Mikhaleva KV; Priadko AS; Filin AV; Vorob'ev SL; Mednikov SN; Luft AV; Kulagin VI; Bagnenko SF
[Ti] Título:[Columnar-celled metaplasia and adenocarcinoma of the esophagus in inhabitants of the Leningrad oblast (by the data of esophagogastroduodenoscopy)].
[So] Fuente:Vestn Khir Im I I Grek;171(6):76-9, 2012.
[Is] ISSN:0042-4625
[Cp] País de publicación:Russia (Federation)
[La] Idioma:rus
[Ab] Resumen:The article presents an analysis of results of 24 384 endoscopic examinations of the upper gastrointestinal tract in population of the Leningrad oblast with symptoms of gastric dyspepsia during the period from 2007 to 2011. The detection of the columnar-celled metaplasia was 1.1%, adenocarcinoma of the esophagus--0.045%. Esophageal adenocarcinoma occurred in 3.95% of cases of the column-celled esophagus. Barrett's esophagus was revealed in males more often than in women (56.5% and 54.5% respectively). The peak incidence of esophageal adenocarcinoma in males was at the age from 46 to 60 years (36.4% of patients), in females--from 61 to 75 years (27.3% of patients). Intestinal metaplasia was detected in 72.7% of cases with esophageal adenocarcinoma: The diagnosis of long and short segment of column-celled esophagus revealed no significant difference in the development of esophageal adenocarcinoma.
[Mh] Términos MeSH primario: Adenocarcinoma/patología
Esófago de Barrett/patología
Endoscopía del Sistema Digestivo/métodos
Neoplasias Esofágicas/patología
Esófago/patología
[Mh] Términos MeSH secundario: Adulto
Anciano
Esófago de Barrett/epidemiología
Diagnóstico Diferencial
Progresión de la Enfermedad
Neoplasias Esofágicas/epidemiología
Femenino
Humanos
Incidencia
Masculino
Metaplasia/epidemiología
Metaplasia/patología
Mediana Edad
Estudios Retrospectivos
Federación de Rusia/epidemiología
[Pt] Tipo de publicación:COMPARATIVE STUDY; ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Mes de ingreso:1305
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:130315
[St] Status:MEDLINE


  10 / 18340 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
[PMID]:22583424
[Au] Autor:Santos FP; Verstovsek S
[Ad] Dirección:Hematology and Stem Cell Transplantation, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
[Ti] Título:JAK2 inhibitors for myelofibrosis: why are they effective in patients with and without JAK2V617F mutation?
[So] Fuente:Anticancer Agents Med Chem;12(9):1098-109, 2012 Nov.
[Is] ISSN:1875-5992
[Cp] País de publicación:Netherlands
[La] Idioma:eng
[Ab] Resumen:An activating mutation (V617F) in the pseudokinase domain of the Janus kinase (JAK)-2 tyrosine kinase has been described in 90% of patients with polycythemia vera (PV) and 50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (MF). The discovery of JAK2V617F stirred the development of JAK2 inhibitors for treatment of patients with MF, ET and PV. Similar to other tyrosine kinase (TK) inhibitors in current use, JAK2 inhibitors target the adenosine triphosphate (ATP) binding site at the TK domain and not the pseudokinase domain, thus affecting both mutated and wild-type kinases. In fact, clinical trials of these compounds have demonstrated improvements in constitutional symptoms and splenomegaly in patients with both mutated and wild-type JAK2 MF. It is believed that these drugs may act not only through inhibition of neoplastic cell proliferation, but also by downregulating signaling through proinflammatory cytokine receptors. In this article, we review the current state of JAK2 inhibitors and discuss why these drugs could be a valuable addition to the treatment armamentarium for patients with and without the JAK2V617F mutation.
[Mh] Términos MeSH primario: Janus Quinasa 2/antagonistas & inhibidores
Mutación Puntual
Mielofibrosis Primaria/quimioterapia
Mielofibrosis Primaria/enzimología
Inhibidores de las Proteína Quinasas/uso terapéutico
[Mh] Términos MeSH secundario: Animales
Benzamidas/uso terapéutico
Benzamidas/toxicidad
Citocinas/inmunología
Humanos
Imidazoles/uso terapéutico
Imidazoles/toxicidad
Janus Quinasa 2/química
Janus Quinasa 2/genética
Janus Quinasa 2/inmunología
Mielofibrosis Primaria/genética
Mielofibrosis Primaria/inmunología
Inhibidores de las Proteína Quinasas/toxicidad
Pirazoles/uso terapéutico
Pirazoles/toxicidad
Piridazinas/uso terapéutico
Piridazinas/toxicidad
Pirimidinas/uso terapéutico
Pirimidinas/toxicidad
Pirrolidinas/uso terapéutico
Pirrolidinas/toxicidad
Sulfonamidas/uso terapéutico
Sulfonamidas/toxicidad
[Pt] Tipo de publicación:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nombre de substancia:
0 (Benzamides); 0 (Cytokines); 0 (INCB018424); 0 (Imidazoles); 0 (LY2784544); 0 (N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide); 0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 0 (Pyridazines); 0 (Pyrimidines); 0 (Pyrrolidines); 0 (Sulfonamides); 0 (TG101348); EC 2.7.10.2 (Janus Kinase 2)
[Em] Mes de ingreso:1305
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:121205
[St] Status:MEDLINE



página 1 de 1834 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud